Checchi Capital Advisers LLC Sells 94 Shares of Danaher Corporation $DHR

Checchi Capital Advisers LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 1.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,004 shares of the conglomerate’s stock after selling 94 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Danaher were worth $1,186,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in DHR. Nuveen LLC bought a new position in shares of Danaher during the first quarter valued at approximately $833,941,000. Invesco Ltd. grew its stake in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP grew its stake in shares of Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after buying an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC grew its stake in shares of Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.20% of the company’s stock.

Danaher Stock Up 2.2%

Danaher stock opened at $215.05 on Monday. The business has a fifty day moving average of $200.19 and a two-hundred day moving average of $197.24. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm has a market cap of $153.98 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.06 and a beta of 0.77. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio is currently 27.23%.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Wells Fargo & Company dropped their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 23rd. Barclays reissued an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research note on Saturday, September 27th. Robert W. Baird increased their price objective on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research note on Friday, July 18th. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.